Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1051 to 1100 of 4090 results for patient

  1. Transvaginal laser therapy for urogenital atrophy (HTG582)

    Evidence-based recommendations on transvaginal laser therapy for urogenital atrophy. This involves using a laser in the vagina to increase its strength and elasticity, to improve symptoms of urogenital atrophy.

  2. Aortic remodelling hybrid stent insertion during surgical repair of an acute type A aortic dissection (HTG634)

    Evidence-based recommendations on aortic remodelling hybrid stent insertion for acute type A aortic dissection. This involves inserting a stent with material sewed on one end into part of the aorta.

  3. Intramedullary distraction for lower limb lengthening (HTG613)

    Evidence-based recommendations on intramedullary distraction for lower limb lengthening in children, young people and adults. This involves surgically inserting a metal lengthening device in the shorter leg.

  4. Hysteroscopic mechanical tissue removal (hysteroscopic morcellation) for uterine fibroids (HTG590)

    Evidence-based recommendations on hysteroscopic mechanical tissue removal (hysteroscopic morcellation) for uterine fibroids in adults. This involves cutting the fibroids into small pieces to remove them.

  5. Midostaurin for untreated acute myeloid leukaemia (TA523)

    Evidence-based recommendations on midostaurin (Rydapt) for untreated FLT3-mutation-positive acute myeloid leukaemia in adults.

  6. Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (TA1023)

    Evidence-based recommendations on elranatamab (Elrexfio) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults.

  7. Transanal total mesorectal excision for rectal cancer (HTG603)

    Evidence-based recommendations on transanal total mesorectal excision for rectal cancer in adults. This involves removing the cancer through the anus or a small cut in the abdomen.

  8. Extracorporeal albumin dialysis for acute liver failure (HTG202)

    Evidence-based recommendations on extracorporeal albumin dialysis for acute liver failure. This involves using a dialysis machine to remove both water-soluble toxins and toxins that are attached to albumin and accumulate in liver failure.

  9. Single-incision short sling mesh insertion for stress urinary incontinence in women (HTG419)

    Evidence-based recommendations on single-incision short sling mesh insertion for stress urinary incontinence in women. This involves putting 2 short slings around the tube that carries urine from the bladder to support it.

  10. Hypoglossal nerve stimulation for moderate to severe obstructive sleep apnoea (HTG455)

    Evidence-based recommendations on hypoglossal nerve stimulation for moderate to severe obstructive sleep apnoea in adults. This involves implanting a device under the skin in the chest and connecting it to a nerve under the tongue (hypoglossal nerve).

  11. Transcranial MRI-guided focused ultrasound thalamotomy for neuropathic pain (HTG491)

    Evidence-based recommendations on transcranial MRI-guided focused ultrasound thalamotomy for neuropathic pain in adults. This involves delivering focused ultrasound to a small part of the brain (in the thalamus) responsible for transmitting pain signals to destroy it.

  12. Percutaneous ultrasound-guided microwave ablation for symptomatic benign thyroid nodules (HTG646)

    Evidence-based recommendations on percutaneous ultrasound-guided microwave ablation for symptomatic benign thyroid nodules. This involves using microwaves from a wire inserted into the nodule to heat and destroy it (ablation).

  13. Percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk percutaneous coronary interventions (HTG492)

    Evidence-based recommendations on percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk percutaneous coronary interventions. This involves inserting temporary pump to support circulation during a heart operation.

  14. Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care (HTG607)

    Evidence-based recommendations on Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care.

  15. High-intensity focused ultrasound for symptomatic benign thyroid nodules (HTG504)

    Evidence-based recommendations on high-intensity focused ultrasound for symptomatic benign thyroid nodules in adults. This involves using heat made by high-frequency sound waves to destroy the nodule.

  16. Immunosuppressive therapy for kidney transplant in adults (TA481)

    Evidence-based recommendations on immunosuppressive therapies for preventing kidney rejection in adults. The therapies are basiliximab (Simulect), immediate-release tacrolimus (Adoport, Capexion, Modigraf, Prograf, Tacni, Vivadex), mycophenolate mofetil (Cellcept and non-branded versions), rabbit anti-human thymocyte immunoglobulin (Thymoglobuline), prolonged-release tacrolimus (Advagraf, Envarsus), mycophenolate sodium (Myfortic, Ceptava), sirolimus (Rapamune), everolimus (Certican) and belatacept (Nulojix).

  17. NICE newsletters and alerts

    Subscribe to NICE newsletters and alerts for the latest healthcare guidance, clinical updates, and evidence-based resources across health and social care.

  18. Percutaneous cementoplasty for palliative treatment of bony malignancies (HTG117)

    Evidence-based recommendations on percutaneous cementoplasty for palliative treatment of bony malignancies. This involves injecting a special cement into the bone in order to stabilise it, reduce pain, or both.

  19. Cryotherapy for the treatment of liver metastases (HTG241)

    Evidence-based recommendations on cryotherapy for the treatment of liver metastases. This involves using cold temperatures applied through a special needle to destroy the cancer cells.

  20. Metatarsophalangeal joint replacement of the hallux (HTG87)

    Evidence-based recommendations on metatarsophalangeal joint replacement of the hallux. This involves removing the problem joint and replacing it with an artificial one.

  21. Radiofrequency-assisted liver resection (HTG136)

    Evidence-based recommendations on radiofrequency-assisted liver resection. This involves using high-frequency radio waves to remove the cancerous part of the liver with minimal blood loss.

  22. Corticosteroid-eluting bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitis (HTG407)

    Evidence-based recommendations on corticosteroid-eluting bioabsorbable stent or spacer insertion during endoscopic sinus surgery for chronic rhinosinusitis in adults. This involves putting a stent (short tube) into the sinus to improve drainage.

  23. New generation cardiac CT scanners (Aquilion ONE, Brilliance iCT, Discovery CT750 HD and Somatom Definition Flash) for cardiac imaging in people with suspected or known coronary artery disease in whom imaging is difficult with earlier generation CT scanners (HTG281)

    Evidence-based recommendations on new generation cardiac CT scanners (Aquilion ONE, Brilliance iCT, Discovery CT750 HD and Somatom Definition Flash) for cardiac imaging in people with suspected or known coronary artery disease in whom imaging is difficult with earlier generation CT scanners.

  24. Nerve transfer to partially restore upper limb function in tetraplegia (HTG466)

    Evidence-based recommendations on nerve transfer to partially restore upper limb function in people with tetraplegia. This involves connecting an undamaged, functioning, but non-essential nerve near the injury to the damaged essential nerve.

  25. Lumasiran for treating primary hyperoxaluria type 1 (HST25)

    Evidence-based recommendations on lumasiran (Oxlumo) for primary hyperoxaluria type 1 in people of all ages.

  26. Hybrid procedure for interim management of hypoplastic left heart syndrome in neonates (HTG158)

    Evidence-based recommendations on hybrid procedure for interim management of hypoplastic left heart syndrome in neonates. This involves placing bands around the branches of the pulmonary artery and inserting stents to keep the ductus arteriosus open.

  27. NICE: backing the healthtech that changes lives

    Following the government’s 10 Year Health Plan for England, we're strengthening our role in getting the best healthtech, including digital tools, diagnostics and medical devices, to patients.

  28. Bringing our guidance together by topic

    We’re bringing our guidance together by topic, so that it’s all in one place, clearer to understand and easier to use.

  29. Highly specialised technologies evaluation committee

    Our recommendations on the use of highly specialised technologies are made by an independent advisory committee

  30. Highly specialised technologies evaluation committee

    Our recommendations on the use of highly specialised technologies are made by an independent advisory committee

  31. Lumbar infusion test for the investigation of normal pressure hydrocephalus (HTG169)

    Evidence-based recommendations on the lumbar infusion test for the investigation of normal pressure hydrocephalus. This involves inserting a lumbar needle into the spinal sac, recording the pressure of the CSF as fluid is infused into the sac.

  32. Transcervical ultrasound-guided radiofrequency ablation for symptomatic uterine fibroids (HTG572)

    Evidence-based recommendations on transcervical ultrasound-guided radiofrequency ablation for symptomatic uterine fibroids in adults. This involves inserting a device through the cervix into the womb to destroy the fibroid using radiofrequency energy.

  33. Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension (TA1009)

    Evidence-based recommendations on latanoprost–netarsudil (Roclanda) for previously treated primary open-angle glaucoma or ocular hypertension in adults.

  34. Endocuff Vision for assisting visualisation during colonoscopy (HTG514)

    Evidence-based recommendations on Endocuff Vision for assisting visualisation during colonoscopy.

  35. Motor neurone disease: assessment and management (NG42)

    This guideline covers assessing and managing motor neurone disease (MND). It aims to improve care from the time of diagnosis, and covers information and support, organisation of care, managing symptoms and preparing for end of life care.

  36. Photodynamic therapy for Barrett's oesophagus (HTG223)

    Evidence-based recommendations on photodynamic therapy for Barrett's oesophagus. This involves using a light-activated drug (called a photosensitising agent) with a laser to destroy the abnormal cells and to promote the growth of healthy cells.

  37. Platelet-rich plasma injections for knee osteoarthritis (HTG497)

    Evidence-based recommendations on platelet-rich plasma injections for knee osteoarthritis in adults. This involves taking plasma from a small amount of the person’s own blood and injecting it into the knee.

  38. Ocrelizumab for treating primary progressive multiple sclerosis (TA585)

    Evidence-based recommendations on ocrelizumab (Ocrevus) for treating primary progressive multiple sclerosis in adults.

  39. Preoperative high dose rate brachytherapy for rectal cancer (HTG383)

    Evidence-based recommendations on preoperative high dose rate brachytherapy for rectal cancers. This involves inserting an applicator into the rectum and using it to deliver radiation to the tumour.

  40. Beta interferons and glatiramer acetate for treating multiple sclerosis (TA527)

    Evidence-based recommendations on beta interferons (Avonex, Betaferon, Extavia, Rebif) and glatiramer acetate (Copaxone) for treating multiple sclerosis in adults.

  41. Endoscopic mucosal resection and endoscopic submucosal dissection of non-ampullary duodenal lesions (HTG232)

    Evidence-based recommendations on endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) of non-ampullary duodenal lesions. This involves using a long camera inserted through the mouth to view the area and removing the abnormal parts of the lining with special instruments.

  42. Type 2 diabetes: insulin degludec (ESNM25)

    Summary of the evidence on insulin degludec for treating type 2 diabetes to inform local NHS planning and decision-making

  43. Endoanchoring systems in endovascular aortic aneurysm repair (HTG625)

    Evidence-based recommendations on endoanchoring systems in endovascular aortic aneurysm repair. This involves using an anchoring device to hold a stent in place to prevent leaks in an aneurysm repair.

  44. Neurostimulation of lumbar muscles for refractory non-specific chronic low back pain (HTG641)

    Evidence-based recommendations on neurostimulation of lumbar muscles for refractory non-specific chronic low back pain in adults. This involves implanting a pulse generator under the skin of the upper buttock or lower back, which the person can use to manage their pain.

  45. Data collection agreement

    treating cystic fibrosis patients with: Ivacaftor, tezacaftor and elexacaftor (Kaftrio®) in combination with ivacaftor for...

  46. Trabeculotomy ab interno for open angle glaucoma (HTG264)

    Evidence-based recommendations on trabeculotomy ab interno for open angle glaucoma. This involves using a specifically designed surgical instrument to remove a portion of tissue, with the aim of improving the eye’s drainage pathway.

  47. Immunosuppressive therapy for kidney transplant in children and young people (TA482)

    Evidence-based recommendations on immunosuppressive therapies for preventing kidney rejection in children and young people. The therapies are basiliximab (Simulect), immediate-release tacrolimus (Adoport, Capexion, Modigraf, Prograf, Tacni, Vivadex), mycophenolate mofetil (Cellcept and non-branded versions), rabbit anti-human thymocyte immunoglobulin (Thymoglobuline), prolonged-release tacrolimus (Advagraf, Envarsus), mycophenolate sodium (Myfortic, Ceptava), sirolimus (Rapamune), everolimus (Certican) and belatacept (Nulojix).

  48. Evidence summaries: unlicensed and off-label medicines – Interim process statement (PMG2)

    This interim process statement sets out to guide the development of 'Evidence summaries: unlicensed and off-label medicines' (ESUOMs). It provides an overview of the key process principles and describes all stages of development for ESUOMs

  49. UrgoStart for treating diabetic foot ulcers and leg ulcers (HTG502)

    Evidence-based recommendations on UrgoStart for treating diabetic foot ulcers and leg ulcers.